Literature DB >> 23764698

Managing irritable bowel syndrome.

Joyce K Anastasi1, Bernadette Capili, Michelle Chang.   

Abstract

OVERVIEW: Irritable bowel syndrome (IBS), characterized by abdominal pain or discomfort associated with a change in bowel patterns, is one of the most common functional gastrointestinal disorders. Because no single drug effectively relieves all IBS symptoms, management relies on dietary and lifestyle modifications, as well as pharmacologic and nonpharmacologic therapies. The authors review current approaches to treatment and discuss nursing implications.

Entities:  

Mesh：

Year:  2013        PMID： 23764698      PMCID： PMC5654469          DOI： 10.1097/01.NAJ.0000431911.65473.35

Source DB:  PubMed          Journal:  Am J Nurs        ISSN： 0002-936X            Impact factor:   2.220


  107 in total

1.  Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial.

Authors:  Susan A Gaylord; Olafur S Palsson; Eric L Garland; Keturah R Faurot; Rebecca S Coble; J Douglas Mann; William Frey; Karyn Leniek; William E Whitehead
Journal:  Am J Gastroenterol       Date:  2011-06-21       Impact factor: 10.864

2.  Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts.

Authors:  Brennan M R Spiegel; Mary Farid; Eric Esrailian; Jennifer Talley; Lin Chang
Journal:  Am J Gastroenterol       Date:  2010-03-02       Impact factor: 10.864

Review 3.  The effect of irritable bowel syndrome on health-related quality of life and health care expenditures.

Authors:  Nikhil Agarwal; Brennan M R Spiegel
Journal:  Gastroenterol Clin North Am       Date:  2011-03       Impact factor: 3.806

4.  Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture.

Authors:  Nanna Goldman; Michael Chen; Takumi Fujita; Qiwu Xu; Weiguo Peng; Wei Liu; Tina K Jensen; Yong Pei; Fushun Wang; Xiaoning Han; Jiang-Fan Chen; Jurgen Schnermann; Takahiro Takano; Lane Bekar; Kim Tieu; Maiken Nedergaard
Journal:  Nat Neurosci       Date:  2010-05-30       Impact factor: 24.884

5.  A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome.

Authors:  Prakash S Masand; Chi-Un Pae; Stan Krulewicz; Kathleen Peindl; Paolo Mannelli; Indu M Varia; Ashwin A Patkar
Journal:  Psychosomatics       Date:  2009 Jan-Feb       Impact factor: 2.386

6.  Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen.

Authors:  John K Marshall; Marroon Thabane; Mark R Borgaonkar; Cindy James
Journal:  Clin Gastroenterol Hepatol       Date:  2007-02-06       Impact factor: 11.382

7.  International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit.

Authors:  Douglas A Drossman; Carolyn Blank Morris; Susan Schneck; Yuming J B Hu; Nancy J Norton; William F Norton; Stephan R Weinland; Christine Dalton; Jane Leserman; Shrikant I Bangdiwala
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

Review 8.  Clinical assessment of irritable bowel syndrome.

Authors:  Tony J Lembo; Rebecca N Fink
Journal:  J Clin Gastroenterol       Date:  2002-07       Impact factor: 3.062

9.  Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial.

Authors:  G Cappello; M Spezzaferro; L Grossi; L Manzoli; L Marzio
Journal:  Dig Liver Dis       Date:  2007-04-08       Impact factor: 4.088

Review 10.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059
View more
  4 in total

Review 1.  Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis.

Authors:  Abigail Marsh; Enid M Eslick; Guy D Eslick
Journal:  Eur J Nutr       Date:  2015-05-17       Impact factor: 5.614

2.  Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Authors:  Marta Sobczak; Gerta Cami-Kobeci; Maciej Sałaga; Stephen M Husbands; Jakub Fichna
Journal:  Eur J Pharmacol       Date:  2014-05-06       Impact factor: 4.432

Review 3.  Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis.

Authors:  Emma Altobelli; Valerio Del Negro; Paolo Matteo Angeletti; Giovanni Latella
Journal:  Nutrients       Date:  2017-08-26       Impact factor: 5.717

4.  Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis.

Authors:  Qinghua Sun; Qiong Jia; Lijin Song; Liping Duan
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.